BUSINESS
    iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
    By Hayate Horiguchi July 14, 2026
    As global pharmaceutical companies pour billions into AI, iPark Institute is exploring ways to build a shared AI drug discovery platform in Japan — arguing that pooling data, computing power, and talent offers the country’s…

    LATEST

    Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
    July 14, 2026
    Quick Look:Three NMEs are up for MHLW panel review on July 27: Insmed’s brensocatib, GSK’s bepirovirsen, and Bayer’s sevabertinib.The session will also cover J&J’s intravesical gemcitabine and BMS’ oral azacitidine, along with label expansions for…
    CEA Review Group Debates Comparator Technologies, ICER Uncertainty
    July 14, 2026
    A health ministry-funded research group conducting technical reviews of Japan’s cost-effectiveness assessment (CEA) system held its third meeting on July 13, discussing comparator technologies and uncertainties surrounding incremental cost-effectiveness ratios (ICERs).The meeting was held behind…
    FDA Greenlights Leqembi Iqlik for Alzheimer’s Initiation Therapy
    July 14, 2026
    The US FDA has approved Leqembi Iqlik, the subcutaneous autoinjector formulation of Eisai’s anti-amyloid antibody Leqembi (lecanemab), as a once-weekly initiation therapy for early Alzheimer’s disease, expanding at-home treatment options from the start of therapy.Eisai…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
    By Kohei Hori

    Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…

    COLUMN

    The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard
    By Philip Carrigan

    Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA